Rekrutuje
Badanie kliniczne
Videolaryngoscopes in the Morbidly Obese
W Polsce: Wkrótce rekrutacjaNa świecie: Rekrutacja wkrótce
Otyłość: badanie kliniczne
Tytuł w rejestrze: Better4All Personalized Intervention
Najważniejsze informacje
- Choroba
- Otyłość (Obesity Prevention)
- Status w Polsce
- Wkrótce rekrutacjarejestr nie podaje osobnego stanu dla Polski, pokazujemy stan całego badania
- Status na świecie
- Rekrutacja wkrótcestan całego badania w rejestrze
- Wiek uczestników
- 18-65 lat
- Płeć
- kobiety i mężczyźni
- Planowana liczba uczestników
- łącznie 1022
- Sponsor
- Harokopio University
- Terminy (planowane)
- 1 października 2025 - 1 kwietnia 2027
- Kraje
- 7: Cypr, Francja, Grecja, Hiszpania, Polska, Portugalia, Szwecja
- Numer w rejestrze
- NCT06997510 (ClinicalTrials.gov)
Gdzie prowadzone jest badanie
Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:
- Uniwersytet Swps (Swps) Wkrótce rekrutacjaWrocławKontakt
rekrutuje wkrótce nie rekrutuje lub brak danych
Kliknij kropkę, żeby zobaczyć ośrodki w mieście.
Więcej badań w tych miastach:
Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
The BETTER4U (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) project, funded by the European Union, aims to address obesity through biologically and behaviourally tailored interventions. Obesity is a major public health issue influenced by genetic, metabolic, and lifestyle factors. Despite current weight management interventions, many individuals face challenges due to these varied influences. The BETTER4U project seeks to improve weight management by incorporating artificial intelligence (AI) and polygenic risk scores (PRS) to personalize interventions. The goal is to test the effectiveness of these personalized interventions in improving weight loss compared to standard care, using advanced monitoring tools and AI models.
The BETTER4ALL personalized intervention is a multicentre, open-label, parallel-group randomized controlled trial (RCT) involving seven study sites across Cyprus, France, Greece, Poland, Portugal, Spain, and Sweden. A total of 1,022 participants with overweight or obesity (BMI ≥ 25 kg/m²), aged 18-65 years, will be enrolled. Participants will be randomized into two groups: an intervention group receiving personalized lifestyle recommendations based on AI and PRS, and a control group receiving standard care recommendations. The intervention will last six months, followed by a six-month follow-up assessment.
The intervention's key aspects include wearable devices and a mobile application to monitor participants' behaviour, including physical activity, sleep, and eating habits. The intervention also integrates genetic, metabolic, and environmental data to provide tailored recommendations for weight loss. Participants' outcomes will be assessed regarding BMI, weight loss maintenance, changes in clinical biomarkers, body composition, and other lifestyle parameters.
This RCT will provide valuable insights into the effectiveness of personalized weight management strategies. AI-driven personalized recommendations and real-time monitoring represent a significant shift from traditional, one-size-fits-all approaches. The results of this study could offer a more effective and sustainable model for obesity management, particularly by accounting for individual genetic predispositions and lifestyle factors. Furthermore, by evaluating the impact of the intervention on a wide range of health outcomes, including biomarkers and psychosocial factors, the study will provide a comprehensive understanding of how personalized interventions can improve overall health and weight management.
In addition to contributing to the scientific understanding of obesity and its management, this project has the potential to influence public health strategies, offering a more personalized, data-driven approach to obesity prevention and treatment. By integrating genetic, environmental, and lifestyle factors, the BETTER4U intervention could pave the way for future innovations in digital health and obesity management.
Leczenie w badaniu
| Lek / interwencja | Rola | Postać, podanie |
|---|---|---|
| Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS) | Interwencja behawioralna | |
| Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months. | Interwencja behawioralna |
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (9)
- Age: Participant aged 18-65 years
- Body Mass Index (BMI): BMI ≥ 25 kg/m² (overweight or obesity)
- Willingness and ability to use wearable devices and an Android mobile application for the duration of the study
- Owning a smartphone device with Android operating system
- Eating utensil technique: dominant hand gestures that correspond to handling of food via a fork or a spoon
- Language proficiency: participant has the ability to read and understand the language in which the mobile app and study materials are provided
- Consent: participant is willing to provide informed consent to participate in the study
- Residency: participant is resident of the country
- Availability: participant is able to participate for the full three-week duration of the study and comply with the study protocol
Kryteria wyłączenia kto nie może wziąć udziału (13)
- Pregnant or breastfeeding or intending to get pregnant in the short-term
- Comorbidities which might affect inflammation levels (i.e. type 1 diabetes, uncontrolled type 2 diabetes, unstable cardiovascular disease, eating disorders, gastrointestinal disorders)
- Mental illness affecting cognitive and communication skills, lifestyle and/or dietary habits
- History of cancer within 5 years prior to intervention onset
- Physical Limitations: any physical or mental condition that would prevent the participant from using the wearable device or mobile application as intended
- Any other criterion which would deem the participant unsuitable, according to the investigator's impression
- Technical Incompatibility: Individual does not own a compatible smartphone or are unable to use the provided wearable devices for technical reasons
- Documented and/or self-reported rapid changes in body weight in the six months preceding intervention onset, attributed to a diagnosed medical condition
- Interventional drug treatment in a clinical trial in the period within six months prior to intervention onset, which might affect intervention impact
- Inability to adhere to the proposed diet regimens, due to medical (i.e. gluten intolerance, allergies, swallowing problems) or religious reasons
- Medication promoting weight loss
- Bariatric surgery in the 12 months preceding intervention onset
- Use of supplements promoting weight loss or sleep quality, mood enhancing supplements, and/or consumption of probiotics and medications that influence the microbiome in the last three months preceding intervention onset Participation in a different clinical trial protocol or participation in different programs aiming at weight loss during the six months preceding intervention onset
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Inne badania: otyłość
RekrutujeFaza III
Cukrzyca: badanie fazy III leku AZD6234
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Badane leki: AZD6234
+8
+8RekrutujeFaza III
Cukrzyca: badanie fazy III leku AZD6234
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Badane leki: AZD6234
+8
+8RekrutujeFaza III
Badanie fazy III leku semaglutide
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
Badane leki: semaglutide
+2
+2RekrutujeFaza III
Badanie fazy III leku ASC30
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Badane leki: ASC30
RekrutujeFaza III
Cukrzyca: badanie fazy III leku ASC30
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Badane leki: ASC30
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.